After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
IMVT belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Immunovant Inc is $5.42B. A total of 0.51 million shares were traded on the day, compared to an average of 1.82M shares.
In the most recent transaction, Van Tuyl Christopher sold 10,813 shares of IMVT for 26.91 per share on Dec 18 ’25. After the transaction, the Chief Legal Officer now owns 149,930 company shares. In a previous transaction on Dec 12 ’25, Roivant Sciences Ltd. bought 16,666,666 shares at 21.00 per share. IMVT shares that Director owns now total 113,317,007.
Among the insiders who sold shares, Fromkin Andrew J. disposed of 22,249 shares on Dec 01 ’25 at a per-share price of $23.25. This resulted in the Director holding 85,852 shares of IMVT after the transaction. In another insider transaction, Hughes Douglas J. sold 15,000 shares at $23.24 per share on Dec 01 ’25. Company shares held by the Director now total 120,773.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, IMVT has a high of $27.69 and a low of $12.72.
As of this writing, IMVT has an earnings estimate of -$0.7 per share for the current quarter. EPS was calculated based on a consensus of 9.0 estimates, with a high estimate of -$0.57 per share and a lower estimate of -$0.76. The company reported an EPS of -$0.76 in the last quarter
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. IMVT’s latest balance sheet shows that the firm has $493.82M in Cash & Short Term Investments as of fiscal 2022. There were $2.36M in debt and $44.52M in liabilities at the time. Its Book Value Per Share was $2.98, while its Total Shareholder’s Equity was $469.82M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IMVT is Buy with a score of 4.44.
